The 'see you at 1.2"? That was a good call Lack of buying is puzzling, anyway I emailed the company with a few questions and I ll post their answer if I receive anything
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%